The development of biopharmaceuticals,driven by advances in molecular cell biology,has accelerated in the past few decades.However,this development presents a paradox,namely,that highly developed biotechnology has led...The development of biopharmaceuticals,driven by advances in molecular cell biology,has accelerated in the past few decades.However,this development presents a paradox,namely,that highly developed biotechnology has led to lower success rates in clinical trials and higher costs in developing individual drugs.This huge obstacle has made drug development the exclusive privilege of large companies and has limited opportunities for small companies to develop advanced drugs.There is also a huge difference between developed and developing countries in terms of their capacity for pharmaceutical research and development(R&D),and high barriers limit the development of innovative drugs in developing countries.展开更多
基金National Key R&D Program of China(2018YFA0900200)and NSFC(31771519).
文摘The development of biopharmaceuticals,driven by advances in molecular cell biology,has accelerated in the past few decades.However,this development presents a paradox,namely,that highly developed biotechnology has led to lower success rates in clinical trials and higher costs in developing individual drugs.This huge obstacle has made drug development the exclusive privilege of large companies and has limited opportunities for small companies to develop advanced drugs.There is also a huge difference between developed and developing countries in terms of their capacity for pharmaceutical research and development(R&D),and high barriers limit the development of innovative drugs in developing countries.
